新型抗凝剂利伐沙班预防心房颤动患者脑栓塞的研究进展  

Research progress of the new anticoagulant drug rivaroxaban in the prevention of cerebral embolism in patients with atrial fibrillation

作　　者：王凤志[1] 何志义[1] 

机构地区：[1]中国医科大学附属第一医院神经内科,沈阳110000

出　　处：《中国新药杂志》2012年第11期1224-1226,共3页Chinese Journal of New Drugs

摘　　要：心房颤动是脑卒中的重要危险因素,药物抗凝治疗是心房颤动一线治疗的首选。传统抗凝剂(如华法林)因出血、频繁监测等原因导致临床应用受限。利伐沙班是一种口服的小分子直接Ⅹa因子抑制剂,作为临床发展的新药,其具有明确的药代动力学及药效学,有望成为传统抗凝剂的替代药物。Atrial fibrillation is an important risk factor for stroke,and anticoagulant treatment is the first-line therapy of atrial fibrillation.Traditional anticoagulants such as warfarin have some limitations such as bleeding and need of frequent monitoring,which make clinical administration difficulty.Rivaroxaban,now undergoing clinical development,is a small molecule,orally active factor Xa direct inhibitor with predictable pharmacokinetics and pharmacodynamics.It is hoped that rivaroxaban will be a promising alternative to the traditional anticoagulants.

关 键 词：抗凝剂 XA因子抑制剂 利伐沙班 心房颤动 卒中 

分 类 号：R973.2[医药卫生—药品]